114 related articles for article (PubMed ID: 36351799)
1. Technologist-Based Implementation of Total Metabolic Tumor Volume into Clinical Practice.
Quinn E; Olson C; Jain MK; Sullivan J; Thorpe MP; Johnson GB; Young JR
J Nucl Med Technol; 2023 Mar; 51(1):57-59. PubMed ID: 36351799
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
[TBL] [Abstract][Full Text] [Related]
3. Just another "Clever Hans"? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer.
Weber M; Kersting D; Umutlu L; Schäfers M; Rischpler C; Fendler WP; Buvat I; Herrmann K; Seifert R
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3141-3150. PubMed ID: 33674891
[TBL] [Abstract][Full Text] [Related]
4. Validation of a Multifocal Segmentation Method for Measuring Metabolic Tumor Volume in Hodgkin Lymphoma.
Camacho MR; Etchebehere E; Tardelli N; Delamain MT; Vercosa AFA; Takahashi MES; Brunetto SQ; Metze IGHL; Souza CA; Cerci JJ; Ramos CD
J Nucl Med Technol; 2020 Mar; 48(1):30-35. PubMed ID: 31604902
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of combined MTV and ADC derived from baseline FDG PET/MRI in aggressive non-Hodgkins lymphoma.
Husby T; Johansen H; Bogsrud TV; Hustad KV; Evensen BV; Boellaard R; Giskeødegård GF; Fagerli UM; Eikenes L
BMC Cancer; 2022 Nov; 22(1):1117. PubMed ID: 36319985
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
Wu LL; Liang JH; Wang L; Xu W; Ding CY
Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
[No Abstract] [Full Text] [Related]
7. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
8. The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in
Driessen J; Zwezerijnen GJC; Schöder H; Drees EEE; Kersten MJ; Moskowitz AJ; Moskowitz CH; Eertink JJ; Vet HCW; Hoekstra OS; Zijlstra JM; Boellaard R
J Nucl Med; 2022 Sep; 63(9):1424-1430. PubMed ID: 34992152
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab.
Eude F; Guisier F; Salaün M; Thiberville L; Pressat-Laffouilhere T; Vera P; Decazes P
Ann Nucl Med; 2022 Mar; 36(3):224-234. PubMed ID: 35060071
[TBL] [Abstract][Full Text] [Related]
11. Extra-thoracic tumor burden but not thoracic tumor burden on (18)F-FDG PET/CT is an independent prognostic biomarker for extensive-disease small cell lung cancer.
Oh JR; Seo JH; Hong CM; Jeong SY; Lee SW; Lee J; Min JJ; Song HC; Bom HS; Kim YC; Ahn BC
Lung Cancer; 2013 Aug; 81(2):218-25. PubMed ID: 23731740
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET/CT Metabolic Tumor Volume and Intratumoral Heterogeneity in Pancreatic Adenocarcinomas: Impact of Dual-Time Point and Segmentation Methods.
Mena E; Sheikhbahaei S; Taghipour M; Jha AK; Vicente E; Xiao J; Subramaniam RM
Clin Nucl Med; 2017 Jan; 42(1):e16-e21. PubMed ID: 27819858
[TBL] [Abstract][Full Text] [Related]
13. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.
Fonti R; Larobina M; Del Vecchio S; De Luca S; Fabbricini R; Catalano L; Pane F; Salvatore M; Pace L
J Nucl Med; 2012 Dec; 53(12):1829-35. PubMed ID: 23071351
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.
van Heek L; Stuka C; Kaul H; Müller H; Mettler J; Hitz F; Baues C; Fuchs M; Borchmann P; Engert A; Dietlein M; Voltin CA; Kobe C
BMC Cancer; 2022 Jun; 22(1):672. PubMed ID: 35717166
[TBL] [Abstract][Full Text] [Related]
15. The correlation of
Qu YH; Long N; Ran C; Sun J
Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
[TBL] [Abstract][Full Text] [Related]
16. Methodological Aspects and the Prognostic Value of Metabolic Tumor Volume assessed with 18F-FDG PET/CT in Lymphomas.
Tutino F; Giovannini E; Pastorino S; Ferrando O; Giovacchini G; Ciarmiello A
Curr Radiopharm; 2022; 15(4):259-270. PubMed ID: 35352655
[TBL] [Abstract][Full Text] [Related]
17. Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from
Schmidkonz C; Krumbholz M; Atzinger A; Cordes M; Goetz TI; Prante O; Ritt P; Schaefer C; Agaimy A; Hartmann W; Rössig C; Fröhlich B; Bäuerle T; Dirksen U; Kuwert T; Metzler M
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1564-1575. PubMed ID: 31853559
[TBL] [Abstract][Full Text] [Related]
18. To evaluate prognostic significance of metabolic-derived tumour volume at staging 18-flurodeoxyglucose PET-CT scan and to compare it with standardized uptake value-based response evaluation on interim 18-flurodeoxyglucose PET-CT scan in patients of non-Hodgkin's lymphoma (diffuse large B-cell lymphoma).
Gupta N; Singh N
Nucl Med Commun; 2020 Apr; 41(4):395-404. PubMed ID: 32073552
[TBL] [Abstract][Full Text] [Related]
19. The predictive recurrence value of MTV-s as an 18F-FDG PET/CT index in patients with IIB-IVA cervical cancer.
Deng C; Ding D; Wang M
Postgrad Med; 2021 May; 133(4):436-443. PubMed ID: 33620285
[No Abstract] [Full Text] [Related]
20. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]